KLK3 and prostate cancer: Recent clinical investigations have shown that when the unique set of prostate tumor genomic biomarkers (232 single nucleotide polymorphisms) was combined with six plasma protein biomarkers there was an improved and correct diagnosis of prostate cancer in five clinical subjects as compared with prostate specific antigen (PSA) alone for the detection of tumor with a seven Gleason score [39,40].